RBC Capital Markets recently revised its outlook for Bicycle Therapeutics plc (BCYC), significantly reducing its price target for the biopharmaceutical company. This adjustment reflects a strategic shift within Bicycle Therapeutics, primarily the decision to discontinue the development of a key drug candidate, zelenectide. The financial implications of this strategic pivot, while aiming for long-term sustainability, introduce near-term uncertainties regarding commercialization pathways.

On March 18, 2026, RBC Capital lowered its price target for Bicycle Therapeutics plc (BCYC) to $7 from a previous $11, maintaining a "Sector Perform" rating. This move came in response to the company's announcement to shift away from zelenectide, a development viewed as a temporary setback for its commercial prospects. However, RBC Capital acknowledged that the ongoing restructuring efforts, including cost-saving initiatives, could lay the groundwork for a more stable future. This aligns with a broader industry trend where biopharmaceutical companies must constantly re-evaluate their portfolios to optimize resource allocation and focus on the most promising drug candidates.

Concurrently, Oppenheimer analyst Jay Olson also adjusted their price target for Bicycle Therapeutics plc (BCYC), moving it from $44 down to $36, while retaining an "Outperform" rating. Olson's analysis highlighted the company's strategic choice to de-emphasize zelenectide-pevedotin, despite some positive data, in favor of reallocating resources towards BT5528 and other next-generation programs, particularly its radio-conjugates portfolio. This decision underscores the complex and high-stakes nature of drug development, where companies often face difficult choices to prioritize certain treatments based on regulatory feedback, market potential, and clinical trial outcomes.

Just prior to these analyst revisions, on March 17, 2026, Bicycle Therapeutics plc (BCYC) released its fourth-quarter earnings report. The company surprised analysts by reporting an EPS of (29 cents), significantly outperforming the consensus estimate of (95 cents). Furthermore, its revenue reached $47.96 million, vastly exceeding the $7.08 million consensus. This revenue surge was primarily attributed to the recognition of remaining collaboration revenues following the termination of agreements with partners such as Novartis and Bayer. Kevin Lee, the CEO, explained that although dose selection for the Duravelo-2 trial was completed, regulatory feedback led to the decision to deprioritize zelenectide for internal development. Instead, the company plans to concentrate on other promising pipeline programs, alongside a broader strategic reprioritization that includes a proposed workforce reduction to streamline operations and enhance efficiency.

Bicycle Therapeutics plc specializes in developing innovative treatments for conditions where current therapeutic options are limited. While the investment potential of BCYC is recognized, the recent strategic adjustments and their financial implications warrant careful consideration from investors. The company's pivot towards new drug candidates and its commitment to operational efficiency signal a proactive approach to navigating the competitive biopharmaceutical landscape, aiming for long-term growth and market relevance.